Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study-Reference-Cited by-同舟云学术

Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study

Published:2017-02-16 Issue:4 Volume:20 Page:460-468
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Bird Paul¹,Nicholls Dave²,Barrett Rina³,de Jager Julien⁴,Griffiths Hedley⁵,Roberts Lynden⁶,Tymms Kathleen⁷,McCloud Philip⁸,Littlejohn Geoffrey⁶⁹,

Affiliation:

1. University of New South Wales and Combined Rheumatology Practice; Kogarah New South Wales Australia

2. Coast Joint Care; Maroochydore Queensland Australia

3. Roche Products, Pty. Limited; Sydney New South Wales Australia

4. Olser House; Southport Queensland Australia

5. Barwon Rheumatology Service; Geelong Victoria Australia

6. Monash Medical Centre; Melbourne Victoria Australia

7. Canberra Rheumatology; Canberra Australian Capital Territory Australia

8. McCloud Consulting Group; Sydney New South Wales Australia

9. Monash University; Melbourne Victoria Australia

Funder

Roche Products Pty Ltd (Australia)

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1756-185X.13036/fullpdf

Reference41 articles.

1. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis;Singh;Arthritis Care Res (Hoboken),2012

2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update;Smolen;Ann Rheum Dis,2014

3. Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis;Markusse;Arthritis Res Ther,2014

4. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year;Kay;Arthritis Res Ther,2014

5. Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents;Pincus;Clin Exp Rheumatol,2014

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gold Nanoparticles Supported Over Biodegradable gum acacia Modified Magnetic Nanoparticles: Characterization and Evaluation of Antioxidant, Cytotoxicity, and Anti-Rheumatoid Arthritic Properties;Journal of Inorganic and Organometallic Polymers and Materials;2024-09-09

2. Disease activity and health‐related quality of life among patients with rheumatoid arthritis with different alcohol consumption habits: comment on the article by Alfredsson et al;Arthritis & Rheumatology;2023-12-20

3. Disease Activity and Health‐Related Quality of Life Among Patients With Rheumatoid Arthritis With Different Alcohol Consumption Habits;Arthritis & Rheumatology;2023-04-12

4. Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials;Rheumatology and Therapy;2022-11-03

5. Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study;Rheumatology and Therapy;2022-10-09